HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 03, March 2019 – Driven by curiosity — Exclusive interview with Nobel laureate Ada Yonath: Her journey in science wasn't always crystal clear       » Your eyes don't deceive you, your brain does       » Organ donations to be computerised in China       » Over One tenth of Chinese people have mental health problems       » AI system can diagnose childhood diseases like doctors       » Bitter rapeseed potential protein source for human nutrition      
INSIDE INDUSTRY
Digital chemotherapy pill that senses and transmit patient information
Success of digital oral oncology medicine will be subject to extent of adoption by patients and physicians

Silicon Valley startup, Proteus Digital Health, in partnership with Fairview Health Services and the University of Minnesota Health system, have launched a digital oral oncology medicine technology.

Each chemotherapy pill, capecitabine, is packed with an ingestible sensor that sends a message to a patch worn by the patient, which then transmits information, such as the time dose, the type of oral chemotherapy taken and certain physiologic responses to medication, to a mobile-friendly platform developed by Proteus.

Edit Kovalcsik, pharma analyst at GlobalData said, “This remote monitoring platform gives providers and caregivers the opportunity to help patients adhere to medication and tailor treatment regimens to individual cancer patients, based on the specific information recorded by the device.”

Proteus already has a digital pill with ingestible sensor – Abilify MyCite, which combines Otsuka Pharmaceuticals’ antipsychotic drug, Abilify (aripiprazole), approved by the U.S. FDA in 2017 for schizophrenia, bipolar disorder and depressive disorder. However, it has demonstrated a very slow take-off as it has not yet been prescribed outside of clinical trials.

Kovalcsik added, “Fast approval processes are critical for software-based digital health solutions because they need constant updating to keep up with the fast-evolving technology.”

As a result, software companies are employing various business strategies to gain a larger patient share where seeking reimbursement is critical to ensure greater patient access through routine prescriptions.

Kovalcsik continued, “The advantage of Proteus’ digital chemotherapy pill is that the sensor is packaged loosely within the capecitabine-containing capsule, which is prescribed routinely by physicians. Unlike in Abilify MyCite, the ingestible sensor is inserted into each capsule by the pharmacist; therefore, it does not require additional FDA approval, as Proteus’ ingestible sensor was FDA-cleared back on 30 July 2012.”

Proteus also arranged for a sort of evidence-based payment structure, where Fairview only makes payments to Proteus if the cancer patient taking the digital chemotherapy is at least 80 percent compliant with the medication.

Proteus is however not alone in the lucrative oncology market. Voluntis, which already has FDA-cleared diabetes management software on the market, Insulia and DIABEO, also aims its pipeline products at the oncology space and has teamed up with Roche.

Kovalcsik concluded, “Nevertheless, the commercial value of these digital technologies in healthcare will be subject to the extent of their adoption by patients and physicians and the implementation of a payment structure that could save cost and resources to the healthcare system.”

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy